Listonstreetpulse.com announces that drug major Genentech is using Arrayit Corporation’s (OTC: ARYC) patented technology in order to accelerate drug discovery. Genentech bought Arrayit’s NanoPrint™ LM60 Microarrayer Platform for $138,000.
Genentech’s research, which was reported in the 2013 edition of Current Protocols in Protein Science, leverages ARYC’s Protein Microarray Technology to screen protein-protein interactions in a massively parallel manner as a means of speeding the identification of new protein drugs.
Proteins, which are the cellular molecules encoded by genes in the human genome, have important therapeutic value. With combined annual sales of around $7.88 billion, Genentech’s protein drug blockbusters include Rituxan, Avastin and Herceptin. Since its acquisition by Roche in 2009, Genentech operates as a member of the Roche Group.
About Arrayit Corporation
Arrayit Corporation is a Sunnyvale, California-based company leading and empowering the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development, and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. The company’s innovative products and services help scientists and clinicians explore the human genome as well as the genomes of plants and animals. Arrayit’s products are used by every major research center in the world.
About Liston Street Pulse
Liston Street Pulse is a leading provider of financial research. The company has significant expertise in U.S. listed small cap and micro-cap stocks. Over the years, Liston Street Pulse’s original and unbiased analysis has helped the investor community immensely.
